mProX™ Human P2RX1 Stable Cell Line

Product Information

Target Family

Other Targets

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;Mouse bone marrow cells

Target Classification

Other Targets Drug Discovery Assays and Products

Target Research Area

CNS Research

Related Diseases

Neurogenic Bladder; Interstitial Cystitis

Gene ID

Human:5023

UniProt ID

Human:P51575

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

P2RX1 is a potential biomarker associated with immune infiltration and prognosis in lung adenocarcinoma (LUAD). It is part of an immune-related signature (CRRS) that can predict overall survival and has superior accuracy compared to clinical variables and molecular features. Low expression of P2RX1 is associated with poor overall survival and decreased immune infiltration. P2RX1 may also be a molecular marker to predict the effect of anti-thrombotic therapy in patients with acute coronary syndrome and atrial fibrillation after percutaneous coronary intervention. Additionally, P2RX1 is involved in subcutaneous adipose tissue alteration in the aging process and is regulated by thyroid hormone signaling. It is also implicated in the macrophage polarization and immune response in lung adenocarcinoma.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human P2RX1 Stable Cell Line (S01YF-1023-PY252). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Cameron Brown (Verified Customer)

How does P2RX1 contribute to inflammation in colitis? Feb 08 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

P2RX1 expression is upregulated in inflamed colon tissues, and targeting P2RX1 can improve the therapeutic efficiency of anti-TNF-α therapy in colitis models, suggesting its role in intestinal inflammation. Feb 08 2020

chat Peyton Davis (Verified Customer)

Can targeting P2RX1 alleviate renal ischemia/reperfusion injury? Jun 19 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

Targeting P2RX1 can preserve mitochondrial dynamics and alleviate renal ischemia/reperfusion injury by influencing the formation of neutrophil extracellular traps. Jun 19 2023

Published Data

Fig.1 Significant suppression of AP severity was observed in the chimeric mice when reconstituted with bone marrow cells lacking P2RX1 (P2RX1-KO) compared to those reconstituted with bone marrow cells from wild-type (WT) mice.

Acute pancreatitis was induced in bone marrow chimeras (WT → WT, KO → KO, WT → KO, and KO → WT) through the intraperitoneal injection of caerulein (50 μg/kg) administered seven times hourly. After 8 hours of caerulein exposure, an analysis of serum amylase activity, pancreas IL1-β levels, and pancreas Cxcl1 expression was undertaken to assess the inflammatory status, with each group consisting of four subjects.

Ref: Dillard, Clémentine, et al. "Expression pattern of purinergic signaling components in colorectal cancer cells and differential cellular outcomes induced by extracellular ATP and adenosine." International Journal of Molecular Sciences 22.21 (2021): 11472.

Pubmed: 34768902

DOI: 10.3390/ijms222111472

Research Highlights

Yang, Siqian. et al. "Identification of a coagulation-related signature correlated with immune infiltration and their prognostic implications in lung adenocarcinoma." Thoracic cancer, 2023.
The study of lung adenocarcinoma (LUAD) has revealed it to be a deadly type of lung cancer with a low survival rate. Researchers have linked the coagulation system to the advancement of tumors and found that an overactive coagulation system can promote immune infiltration and the growth of cancer cells, leading to a detrimental outlook for cancer patients. Despite this, the viability of using coagulation-related genes (CRGs) as a prognostic tool for LUAD is yet to be established. To address this, the authors developed an immune-related signature (CRRS) and discovered a potential coagulation-related biomarker (P2RX1).
Yang, Siqian. et al. "Identification of a coagulation-related signature correlated with immune infiltration and their prognostic implications in lung adenocarcinoma." Thoracic cancer, 2023.
Pubmed: 37795779 DOI: 10.1111/1759-7714.15121

Li, Jingrui. et al. "Identification of Molecular Markers Predicting the Outcome of Anti-thrombotic Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome and Atrial fibrillation: Evidence from a Meta-analysis and Experimental Study." Journal of cardiovascular translational research, 2023.
In clinical practice, it is common for patients to have both acute coronary syndrome (ACS) and atrial fibrillation (AF). This often results in a critical condition with a high risk of both ischemia and bleeding. The present study conducted a meta-analysis of microarray data from the GEO database to identify potential molecular markers for predicting the efficacy of ACS and AF treatment. In a group of 40 patients who underwent PCI, the effects of P2RX1 on platelet aggregation, medication resistance, and predictive value were evaluated. After PCI, 20 up-regulated genes in peripheral blood samples were found to be down-regulated while 7 down-regulated genes were up-regulated. Furthermore, the study also identified eight potential genes affected by ACS. Interestingly, P2RX1, which was one of the four LASSO analysis-retrieved disease characteristic genes, showed promise in predicting the risk of thrombosis in AF patients and the anti-thrombotic impact of PCI. Thus, P2RX1 may serve as a valuable molecular marker for predicting the effectiveness of anti-thrombotic therapy in patients with ACS and AF following PCI.
Li, Jingrui. et al. "Identification of Molecular Markers Predicting the Outcome of Anti-thrombotic Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome and Atrial fibrillation: Evidence from a Meta-analysis and Experimental Study." Journal of cardiovascular translational research, 2023.
Pubmed: 37672183 DOI: 10.1007/s12265-023-10416-3